

# Norway

Population 2015

5.2 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.011 (0.011–0.011)	0.21 (0.2–0.22)
Mortality (HIV+TB only)	<0.01 (0–<0.01)	0.02 (0–0.1)
Incidence (includes HIV+TB)	0.33 (0.28–0.38)	6.3 (5.4–7.3)
Incidence (HIV+TB only)	<0.01 (<0.01–0.01)	0.15 (0.12–0.19)
Incidence (MDR/RR-TB)**	0.01 (<0.01–0.019)	0.19 (0.04–0.36)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–0.015)	0.11 (0.081–0.15)	0.12 (0.084–0.16)
Males	0.016 (0.011–0.021)	0.19 (0.15–0.23)	0.2 (0.16–0.25)
Total	0.025 (0.019–0.032)	0.3 (0.28–0.33)	0.33 (0.28–0.38)

## TB case notifications, 2015

Total cases notified	318
Total new and relapse	286
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	
- % pulmonary	70%
- % bacteriologically confirmed among pulmonary	89%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.04 (0.03–0.05)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	11	
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			7 (1–12)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.86–6)	4.8% (0.12–24)	
% notified tested for rifampicin resistance	71%	47%	238
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 6, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 5, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	84%	293
Previously treated cases, excluding relapse, registered in 2014	80%	20
HIV-positive TB cases, all types, registered in 2014	77%	13
MDR/RR-TB cases started on second-line treatment in 2013	83%	6
XDR-TB cases started on second-line treatment in 2013		0

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)	
------------------------------------	--

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB